ENO2 and asthma: Notably, in the male/female subgroup, the sIgE + subgroup, the ECRSwNP subgroup, and the NSE ±subgroup, patients’ asthma control scores showed a significant improvement compared with baseline; nineteen of 22 patients (86.36%) reached the asthma control level (ACT scores >20) after 24-week treatment of omalizumab.